Kezar Study Evaluates Potential New Treatment for People with Lupus Nephritis
PALIZADE is a Phase 2b, randomized, controlled, double-blind, multicenter study evaluating the efficacy and safety of zetomipzomib (KZR-616) 30 mg or 60 mg vs. placebo in patients with active lupus nephritis. Sponsored by Kezar Life Sciences, it involves screening, 52 weeks of treatment, and a follow-up visit. Participants must meet specific criteria, including age, biopsy results, and lab values, and cannot have certain medical conditions or received specific treatments. The study is placebo-controlled, double-blind, and conducted globally.
Highlighted Terms
Related News
PALIZADE is a Phase 2b, randomized, controlled, double-blind, multicenter study evaluating the efficacy and safety of zetomipzomib (KZR-616) 30 mg or 60 mg vs. placebo in patients with active lupus nephritis. Sponsored by Kezar Life Sciences, it involves screening, 52 weeks of treatment, and a follow-up visit. Participants must meet specific criteria, including age, biopsy results, and lab values, and cannot have certain medical conditions or received specific treatments. The study is placebo-controlled, double-blind, and conducted globally.